Oxford Ledge
Search
No licensed closing price on file for AVIR. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:45 UTC.
Cipher Digital is a late-stage clinical biopharmaceutical company developing oral antiviral medications for serious viral diseases. The company's primary focus is a combination regimen of bemnifosbuvir and ruzasvir for hepatitis C virus infection, which the company believes offers improvements over current treatment standards through a shorter duration and reduced drug interactions.
Summarized from Atea Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
| Valuation | |
| EPS (FY2021) | $1.37 |
| Return on equity | 17.07% |
Cipher Digital is a late-stage clinical biopharmaceutical company developing oral antiviral medications for serious viral diseases.
Atea Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-22. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:45 UTC. This page is also available as JSON at /api/data?ticker=AVIR and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for AVIR and 5,000+ tickers.
Create a free account — keep AVIRGET /api/data?ticker=AVIR
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt